Yan Leyfman: Long-Term Hope in RRMM
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent article by Sundar Jagannath et al. published in Journal of Clinical Oncology:
“Long-term hope in RRMM:
Final results from CARTITUDE-1 show ciltacabtagene autoleucel (cilta-cel) delivers deep, durable responses in heavily pretreated relapsed/refractory multiple myeloma.
Key Highlights:
- Median OS: 60.7 months
- 1/3 of patients (32/97) are alive and progression-free ≥5 years after a single infusion, with no maintenance
- All assessed long-term responders were MRD- and PET/CT-negative at year 5+
- Favorable biomarkers: lower tumor burden, higher naïve T cells, better T/N ratio and hematologic parameters
- Safety remained consistent
First data suggesting curative potential of cilta-cel in RRMM.”
Title: Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Authors: Sundar Jagannath, Thomas Martin, Yi Lin, Adam Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus Berdeja, Alexander Lesokhin, Jessica Liegel, Adriana Rossi, Alex Lieberman-Cribbin, Saad Usmani, Binod Dhakal, Samir Parekh, Hui Li, Feng Wang, Rocio Montes de Oca, Vicki Plaks, Huabin Sun, Arnob Banerjee, Jordan Schecter, Nikoletta Lendvai, Deepu Madduri, Tamar Lengil, Jieqing Zhu, Mythili Koneru, Muhammad Akram, Nitin Patel, Octavio Costa Filho, Andrzej Jakubowiak, Peter Voorhees
Read the Full Article on Journal of Clinical Oncology
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023